RJ Reynolds Vapor Co. has been denied a request to have their September loss reevaluated after being ordered to pay $95 million in damages to Altria Group for violating three vape pod patents with their Vuse Alto electronic cigarettes.
According to reports, Judge N. Carlton Tilley Jr. stated in an opinion released on Thursday in the U.S. District Court for the Middle District of North Carolina that "the jury's disagreement with Reynolds' perspective does not mean the trial was unfair.
Tilley refused the motion made by Reynolds, a subsidiary of BAT, to either retry or reduce the compensation awarded to Altria's customer service company by the jury on September 7th.
In its request for a retrial, Reynolds Vaper argues that "Altria improperly injected provocative evidence regarding allegations of patent infringement against Reynolds in other cases, depriving Reynolds of a fair trial. The erroneous evidence ruling also harmed Reynolds' defense. These errors, taken independently and under the cumulative error doctrine, affected the verdict and thus require a complete retrial.
Altria stated that "this was a fair trial. There is no reason for a retrial, and we are pleased that the jury correctly determined that Reynolds Vapor Company infringed on some of our patents.
Disclaimer
This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.
Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.
The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.
This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.
Copyright Notice
This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.
No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.
For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.
AI-Assisted Translation and Editing Notice
Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.
Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.
